Linperlisib tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Brand
- Intalvia
- Company
- Shanghai Yingli Pharmaceutical
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- For adults with relapsed or refractory follicular lymphoma after at least two previous systemic treatments.
- Indication source and scope
- Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- Prescribing-information limitations
- Indications checked against an official public submission. The full original prescribing information is still unavailable.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Not matched in the 2025 national list; manual review pending
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance verification notes
- No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.
Sources
- https://yjj.sh.gov.cn/sjdt/20221109/da00bc872349418daf7476502e936e49.html
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.nhsa.gov.cn/attach/Ypsn2025/YPSN202500074/YPSN202500074.pdf
Open the interactive record, public price references and discussions